Hospital
Community Hospital of Anderson & Madison County, INC
Community Hospital of Anderson & Madison County, INC was paid $32.30M by Medicaid between Jan 2018 and Dec 2024, across 179 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoCOMMUNITY HOSPITAL OF ANDERSON & MADISON COUNTY, INC
ANDERSON, IN 46011
ANDERSON, IN 46011
33aNPI1972500452assigned 06/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.30M
24GClaims679,692
24DCodes billed179
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#11 of 69
Median peer was paid$9.76M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,026 | $1.43M | |
| 2019 | 68,978 | $2.66M | |
| 2020 | 55,501 | $2.40M | |
| 2021 | 101,042 | $5.25M | |
| 2022 | 147,174 | $7.37M | |
| 2023 | 127,515 | $7.56M | |
| 2024incomplete | 98,456 | $5.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 46,194 | 40,474 | $7.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 45,212 | 37,953 | $6.76M |
| 71045 | Radiologic examination, chest; single view | 6.8% | 16,334 | 13,580 | $2.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 15,966 | 13,253 | $1.80M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 4,585 | 3,745 | $1.59M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.7% | 25,494 | 20,624 | $1.51M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.1% | 5,972 | 5,061 | $1.33M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 6,728 | 6,203 | $931K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 7,712 | 5,214 | $877K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.7% | 2,084 | 895 | $857K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 18,561 | 15,255 | $775K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 7,303 | 1,723 | $638K |
167 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 8,871 | $565K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 7,168 | $539K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 11,301 | $495K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 4,592 | $453K |
| 80050 | General health panel | 1.1% | 1,962 | $371K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,115 | $281K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,292 | $259K |
| 87428 | <1% | 8,561 | $228K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,765 | $194K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,496 | $192K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,689 | $172K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 742 | $163K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 652 | $162K |
| 94761 | <1% | 5,079 | $144K | |
| 80053 | Comprehensive metabolic panel | <1% | 27,432 | $137K |
| 84484 | <1% | 20,527 | $125K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 406 | $73K |
| 80061 | Lipid panel | <1% | 9,737 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,165 | $68K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,681 | $60K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,492 | $60K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,564 | $59K |
| 77336 | <1% | 460 | $55K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 65 | $54K |
| 81025 | <1% | 9,444 | $52K | |
| 80076 | <1% | 9,275 | $44K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 742 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,961 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,501 | $37K |
| 83690 | <1% | 11,539 | $37K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 469 | $34K |
| 81001 | <1% | 20,017 | $34K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 23 | $28K |
| 87807 | <1% | 2,862 | $27K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 123 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 794 | $25K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 793 | $25K |
| 86481 | <1% | 399 | $25K | |
| 82607 | <1% | 2,440 | $24K | |
| 86703 | <1% | 1,998 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,442 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,092 | $21K |
| 95819 | <1% | 41 | $20K | |
| 64615 | <1% | 110 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 937 | $20K |
| 86803 | <1% | 1,558 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 501 | $19K |
| 87653 | <1% | 751 | $19K | |
| 86480 | <1% | 324 | $18K | |
| 97161 | <1% | 197 | $18K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,074 | $17K |
| 86708 | <1% | 1,453 | $17K | |
| 59025 | Fetal non-stress test | <1% | 189 | $17K |
| 93017 | <1% | 145 | $17K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 65 | $16K |
| 86706 | <1% | 1,504 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 855 | $15K |
| 80074 | <1% | 240 | $11K | |
| 83735 | <1% | 2,332 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 74 | $9K |
| 81003 | <1% | 7,322 | $9K | |
| 83880 | <1% | 515 | $8K | |
| 77334 | <1% | 53 | $8K | |
| 86592 | <1% | 2,135 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 331 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 180 | $7K |
| 86140 | <1% | 2,682 | $7K | |
| 95886 | <1% | 14 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 59 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $6K |
| 82977 | <1% | 741 | $5K | |
| 82746 | <1% | 662 | $5K | |
| 82728 | <1% | 684 | $5K | |
| 84439 | <1% | 1,006 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 106 | $4K |
| 86235 | <1% | 117 | $4K | |
| 83550 | <1% | 778 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 408 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 79 | $4K |
| 85652 | <1% | 2,562 | $4K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 102 | $3K |
| 83540 | <1% | 777 | $3K | |
| 86200 | <1% | 414 | $3K | |
| 77300 | <1% | 16 | $3K | |
| 87340 | <1% | 354 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 35 | $2K |
| 72202 | <1% | 44 | $2K | |
| 86787 | <1% | 291 | $2K | |
| 86705 | <1% | 199 | $2K | |
| 86038 | <1% | 330 | $2K | |
| 72100 | <1% | 65 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 25 | $2K |
| 36416 | <1% | 418 | $2K | |
| 87631 | <1% | 34 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 88 | $2K |
| 87536 | <1% | 29 | $2K | |
| 87081 | <1% | 386 | $2K | |
| 85379 | <1% | 253 | $2K | |
| 84550 | <1% | 730 | $1K | |
| 80055 | <1% | 59 | $1K | |
| 82570 | <1% | 460 | $1K | |
| 85027 | <1% | 271 | $1K | |
| 94060 | <1% | 19 | $1K | |
| 82043 | <1% | 379 | $1K | |
| 74018 | <1% | 30 | $1K | |
| 84460 | <1% | 401 | $1K | |
| 82550 | <1% | 764 | $1K | |
| 86762 | <1% | 112 | $1K | |
| 82955 | <1% | 169 | $857.98 | |
| 84702 | <1% | 59 | $755.73 | |
| 86431 | <1% | 251 | $685.58 | |
| 86850 | <1% | 173 | $584.11 | |
| 94726 | <1% | 67 | $545.54 | |
| 73130 | <1% | 17 | $530.72 | |
| 82553 | <1% | 534 | $501.38 | |
| 86160 | <1% | 46 | $489.19 | |
| 84146 | <1% | 26 | $479.53 | |
| 80069 | <1% | 92 | $465.25 | |
| 82950 | <1% | 123 | $413.91 | |
| 80305 | <1% | 55 | $399.18 | |
| 83605 | <1% | 64 | $298.95 | |
| 96376 | <1% | 105 | $295.62 | |
| 86361 | <1% | 16 | $252.76 | |
| 82962 | <1% | 185 | $240.84 | |
| 86900 | <1% | 111 | $218.30 | |
| 86901 | <1% | 111 | $195.23 | |
| 87905 | <1% | 50 | $194.78 | |
| 86225 | <1% | 33 | $186.86 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 170 | $186.40 |
| 85610 | <1% | 128 | $185.46 | |
| 87040 | <1% | 24 | $160.16 | |
| 83516 | <1% | 34 | $156.81 | |
| 87077 | <1% | 30 | $129.28 | |
| 86709 | <1% | 14 | $123.86 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 837 | $121.41 |
| 87808 | <1% | 12 | $120.48 | |
| 84156 | <1% | 48 | $108.50 | |
| 85007 | <1% | 28 | $79.69 | |
| 82947 | <1% | 18 | $78.83 | |
| 83020 | <1% | 16 | $77.53 | |
| 84100 | <1% | 30 | $76.26 | |
| 82610 | <1% | 14 | $75.75 | |
| 81015 | <1% | 35 | $45.55 | |
| 87210 | <1% | 26 | $33.84 | |
| 82248 | <1% | 17 | $29.22 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,260 | $21.17 |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 144 | $18.30 |
| 85014 | <1% | 14 | $13.42 | |
| 85018 | <1% | 14 | $13.42 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,993 | $12.05 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,442 | $8.36 |
| 84450 | <1% | 12 | $6.98 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 1,423 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 120 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 18 | $0.00 |
| 99080 | 0% | 54 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| 94729 | 0% | 47 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,112 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 366 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 65 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 515 | $0.00 |
| 88304 | 0% | 37 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 391 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 87 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLARD, HOLLY (FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Community Health Network, INC | Indianapolis, IN | $161.73M |
| Community Health Network, INC | Indianapolis, IN | $32.97M |
| Community Hospital South, INC. | Indianapolis, IN | $27.35M |
| Fairbanks Hospital, INC. | Indianapolis, IN | $18.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.